Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ULURU, a specialty pharmaceutical company, has reported total revenues of $75,171 for the first quarter ended 31 March 2011, as compared to $235,230 for the same period in 2010.
Subscribe to our email newsletter
The decrease of $160,000 in revenue was due primarily to a decrease in Aphthasol product sales during the first quarter of 2011.
ULURU has reported a net loss of $1.16m, or $0.01 loss per diluted share, compared to net loss of $1.3m or $0.02 loss per diluted share, for the same period last year.
The company’s operating loss for the first quarter ended 31 March 2011, was $1.15m, as compared to $1.29m for the same period prior year.
ULURU president CEO Kerry Gray said their business plan for the balance of 2011 includes significant revenue growth as their products are introduced into additional global markets.